| Document |
Document Title |
|
WO/2018/001084A1 |
The present invention relates to the field of pharmaceutical chemistry. Disclosed are a heat shock protein inhibitor, and a manufacturing method and application thereof. The heat shock protein inhibitor has a characteristic structure rep...
|
|
WO/2018/001197A1 |
Provided is a method for preparing an URAT1 inhibitor 2-((5-bromo-4-((4-bromonaphthalen-1-yl)methyl)-4H-1,2,4-tria
zol-3-yl)thio)acetic acid as represented by the following formula ZXS-BR, the reaction equation thereof being as follows. ...
|
|
WO/2018/005914A1 |
Methods for treating HIV or AIDS in a human are provided using two drug regimens comprising a bictegravir and rilpivirine, as well as compositions containing such compounds.
|
|
WO/2017/223016A1 |
The present invention provides compounds of Formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA rec...
|
|
WO/2017/219083A1 |
The present invention relates to novel compounds which active HIV expression in latently infected cells. More particularly, the invention relates to pharmaceutical compositions comprising the novel compounds and their use in activating H...
|
|
WO/2017/221083A1 |
The compositions and compounds of formula I which includes ribavirin conjugates or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These conjugates may be formulated as pharmaceutical compositions. The pharmac...
|
|
WO/2017/220467A1 |
The invention relates to compounds of general formula (I), to the agrochemically compatible salts thereof, to a method for the production thereof and to the use thereof in the field of plant protection.
|
|
WO/2017/217553A1 |
[Problem] To provide a novel agricultural chemical, and particularly an herbicide. [Solution] An oxime compound represented by formula (1) and an herbicide containing the same. (In formula (1): B represents B-1 or the like; Q represents ...
|
|
WO/2017/215589A1 |
A halogenated compound, an axially chiral isomer thereof, and an application thereof in preparing drugs for disorders closely related to aberrant levels of uric acid.
|
|
WO/2017/210694A1 |
The present disclosure is directed to triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to m...
|
|
WO/2017/209155A1 |
Provided are: a novel sulfonamide compound having ribonucleotide reductase inhibitory activity or a salt thereof; and a pharmaceutical composition which contains this sulfonamide compound or a salt thereof as an active ingredient. A comp...
|
|
WO/2017/203083A1 |
The present invention relates to 1,2,3-triazoles of formula (I), which can be used to improve or restore intracellular calcium homeostasis and RyR-calstabin binding in human and animal cells. The invention also relates to methods for syn...
|
|
WO/2017/197909A1 |
The invention describes a new crystalline form of sulfentrazone and its preparation process. The invention also describes the analyses of the crystal through various analytical methods and the use of the crystal to prepare stable agroche...
|
|
WO/2017/200857A1 |
Provided are methods for treating or preventing a fibrotic disease selected from systemic sclerosis, cystic fibrosis, non-alcoholic steatohepatitis, Peyronie's disease, or interstitial lung disease; the method comprising administering a ...
|
|
WO/2017/194716A1 |
The present application relates to certain substituted imidazole and triazole compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating pain, musculoskeletal inflammation, neuroinfl...
|
|
WO/2017/195149A1 |
Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.
|
|
WO/2017/197047A1 |
Compositions and methods for inhibiting corrosion of metallic surfaces in contact with an aqueous medium such as copper, copper alloy, and steel surfaces of an open recirculating cooling water system. In certain embodiments, an aromatic ...
|
|
WO/2017/197080A1 |
The present invention is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods. Diseases and conditions that can be treated with the compounds and compositions of the invention include,...
|
|
WO/2017/195216A1 |
The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and...
|
|
WO/2017/191115A1 |
The present invention relates to novel Oxoalkyl-substituted 1-phenyl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compoun...
|
|
WO/2017/189893A1 |
Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pa...
|
|
WO/2017/183625A1 |
[Problem] To provide an organic electroluminescence element comprising, in order to improve the element characteristics of the organic EL element, in particular, so as to absorb 400-410 nm wavelength sunlight and not have effects on an i...
|
|
WO/2017/184808A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen or C1-C6 alkyl; ring A is cyclohexyl or phenyl, optionally substituted; ring B is aryl or a nitrogen-containing heteroaryl...
|
|
WO/2017/184491A1 |
The present embodiments provide for substituted triazolylpyridine derivative compounds, and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for modulating the activity of histone d...
|
|
WO/2017/170183A1 |
A composition containing a compound having a substituent indicated by general formula (1). (In the formula, R1 and R2 each independently indicate a hydrogen atom, a halogen atom, a cyano group, a hydroxyl group, a nitro group, a carboxyl...
|
|
WO/2017/170182A1 |
A photosensitive composition containing a compound having a substituent indicated by general formula (1). (In the formula, R1 and R2 each independently indicate a hydrogen atom, a halogen atom, a cyano group, a hydroxyl group, a nitro gr...
|
|
WO/2017/171095A1 |
Provided is a method for producing an azole derivative (I), which is reduced in the number of necessary steps. A method for producing an azole derivative (I) according to the present invention comprises: an olefination step for obtaining...
|
|
WO/2017/170826A1 |
The purpose of the invention is to provide a compound useful in the prevention or treatment of diabetes, obesity, and conditions related thereto. The present invention relates to an enhancing agent for glucagon-like peptide-1 receptor ac...
|
|
WO/2017/165256A1 |
The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly ...
|
|
WO/2017/165139A1 |
In an aspect, the invention relates to 1,4,5 -substituted 1,2,3-triazole and 1,2,4,5- substituted imidazoles, which are modulators the pregnane X receptor ("PXR"); synthesis methods for making the compounds; pharmaceutical compositions c...
|
|
WO/2017/160669A1 |
Insulin-incretin conjugates comprising a peptide having agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, and/or the gastric inhibitory protein (GIP) receptor conjugated to an insulin molecule having ...
|
|
WO/2017/156688A1 |
Disclosed in the present invention is a preparation method for a nitroolefin derivative, the method comprising the following steps: adding an ethylene compound, sodium nitrite, manganese dioxide and 2,2,6,6-tetramethylpiperidinyloxy to a...
|
|
WO/2017/157735A1 |
The invention relates to the use of a compound of general formula (I) in which M and D have the meanings given in the description for controlling animal pests.
|
|
WO/2017/152685A1 |
Provided are an additive for polymer as represented by formula I and a method for preparing same, and a polymer composition comprising the additive, wherein R1 and R2 are the same or different, representing H, a C1-C8 alkyl group, or a C...
|
|
WO/2017/152712A1 |
Disclosed are the crystalline form of amicarbazone of formula (Ⅰ), the crystal preparation process, the analyses of the crystal through various analytical methods and using the crystal to prepare stable agrochemical formulation. Also d...
|
|
WO/2017/156255A1 |
The present invention is directed to compounds, compositions and methods for preventing, treating or curing Hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts...
|
|
WO/2017/156354A1 |
The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, said compound having the structure : Formula (I)
|
|
WO/2017/152842A1 |
Compounds that inhibit kinase Lck or Btk, pharmaceutically acceptable salts, hydrides, stereoisomers and pharmaceutical compositions thereof are disclosed.
|
|
WO/2017/155050A1 |
Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity. A compound represented by formula (I) [wherein each symbol is as defined in the description] or a salt thereof has a cholinergic m...
|
|
WO/2017/148416A1 |
Disclosed are a method for preparing maytansine esters as shown by formula (I) and an intermediate thereof. The method comprises a step of carrying out an interesterification reaction of compound (Ia) and RCOOR' in the presence of an org...
|
|
WO/2017/147270A1 |
Atropisomers of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety...
|
|
WO/2017/143803A1 |
The present invention relates to the field of agricultural bactericides. Disclosed are a novel bactericidal compound having significant effects in plant disease control, a bactericidal composition and preparation comprising the bacterici...
|
|
WO/2017/145024A1 |
Described herein are water-soluble UV-absorbing vinylic monomers and their uses in preparing UV-absorbing contact lenses capable of blocking ultra-violet ("UV") radiation and optionally (but preferably) violet radiation with wavelengths ...
|
|
WO/2017/136589A1 |
Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of ...
|
|
WO/2017/131380A1 |
The present specification relates to a heterocyclic compound and an organic light emitting device containing the same.
|
|
WO/2017/132528A1 |
The present disclosure relates to triazole derivatives of melampomagnolide B, their synthesis, and their use as anti-cancer compounds.
|
|
WO/2017/126847A1 |
The present invention relates to a method for preparing a 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofurane-2-yl)
propanol derivative simply and in high yield, and an intermediate therefor.
|
|
WO/2017/125634A1 |
The invention relates to compounds having formula (I) wherein A is selected from the group consisting of: a) optionally substituted (C1-C8) alkyl; b) optionally substituted (C3-C6) cycloalkyl; c) optionally substituted (C6-C14) aryl; d) ...
|
|
WO/2017/118193A1 |
The present invention relates to the field of agricultural fungicides and discloses a compound having a fungicidal activity, a fungicide composition and preparation using the compound as an active ingredient, and a use thereof. The struc...
|
|
WO/2017/117529A1 |
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using ...
|
